Key result
RAAS inhibition modestly lowers NT-proBNP in systemic right ventricles without improving RVEF or exercise capacity.
Why the study?
Evidence for RAAS inhibition in systemic right ventricle remains scarce, and current practice is largely based on extrapolation from left ventricular studies and expert consensus.
Does RAAS inhibition improve NT-pro-BNP, RVEF, or VO2-max in adult patients with a systemic right ventricle?
Meta-Analysis (n=325)
Does RAAS inhibition improve NT-pro-BNP, RVEF, or VO2-max in adult patients with a systemic right ventricle?
RAAS inhibition in patients with a systemic right ventricle safely reduces NT-pro-BNP levels but does not improve right ventricular ejection fraction or peak oxygen uptake in the short term.
Answers are grounded in this paper and cite their sources.
Does not support routine RAAS inhibition to improve RV function or exercise capacity in systemic right ventricle; challenges extrapolation from left ventricular heart failure trials.
Introduction Pharmacological therapy has transformed the management of heart failure, yet pivotal trials have primarily focused on acquired left ventricular disease. Evidence for renin-angiotensin-aldosterone system (RAAS) inhibition in systemic right ventricle (sRV) remains scarce, and current practice is largely based on extrapolation from left ventricular studies and expert consensus. This meta-analysis evaluates the efficacy and safety of RAAS blockade in patients with a failing sRV. Methods A PubMed search identified studies investigating RAAS inhibition in sRV failure. Reported outcomes included changes in NT-pro-BNP, right ventricular ejection fraction (RVEF), and peak oxygen uptake (VO 2 -max). Data were analyzed using conventional statistics and visualized with forest plots. Results Ten eligible studies were included, comprising a pooled cohort of 325 patients, of which 261 received active treatment. The population was predominantly male (67.1%), with mean cohort ages ranging from 25.2 to 48.5 years. Mean treatment durations spanned 3.5 to 37.2 months. RAAS inhibition was associated with a reduction in NT-pro-BNP (Cohen’s d = –0.28, 95% CI –0.49 to –0.07, p = 0.009). However, no improvements in RVEF or VO 2 -max were observed. The therapy was generally well-tolerated. The overall mortality incidence was 5.6 deaths per 1,000 person-years in the active treatment groups. Conclusion The evidence for RAAS inhibition in patients with sRV is limited but suggests a beneficial reduction in NT-pro-BNP, indicating a hemodynamic effect but without improvements in RVEF or VO 2 -max. When combined with extrapolated data from large left ventricular heart failure trials, these findings support that RAAS inhibition is safe and may be considered in patients with sRV failure.
No takes yet. Share an insight, caveat, or question.
Baroudi et al. (2026) conducted a meta-analysis in Systemic right ventricle (sRV) failure (n=325). RAAS inhibition (ACEi, ARB, MRA, or ARNI) vs. Control or baseline was evaluated on Change in NT-pro-BNP (Cohen's d -0.28, 95% CI -0.49 to -0.07, p=0.009). RAAS inhibition reduced NT-pro-BNP levels in patients with a systemic right ventricle, but did not improve right ventricular ejection fraction or exercise capacity.
Synapse has enriched 10 related papers. Consider them for comparative context: